{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:50:53Z","timestamp":1776941453580,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mayo Clinic Center for Clinical and Translational Science (CCaTS) Benefactor Career Development Award"},{"name":"American Cancer Society (ACS) Clinician Scientist Development Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00779-0","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:15:47Z","timestamp":1776939347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline DDX41 Variants: Current Understanding and Future Directions"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-9153","authenticated-orcid":false,"given":"Aldo A.","family":"Acosta-Medina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"issue":"20","key":"779_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"779_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"7","key":"779_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"2","key":"779_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"K-l Huang","year":"2018","unstructured":"Huang K-l, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355\u2013370.e314.","journal-title":"Cell"},{"issue":"7","key":"779_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1182\/blood.2021015135","volume":"140","author":"P Li","year":"2022","unstructured":"Li P, Brown S, Williams M, et al. The genetic landscape of germlineDDX41variants predisposing to myeloid neoplasms. Blood. 2022;140(7):716\u201355.","journal-title":"Blood"},{"issue":"11","key":"779_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/ajh.26321","volume":"96","author":"ES Martin","year":"2021","unstructured":"Martin ES, Ferrer A, Mangaonkar AA, et al. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021;96(11):1450\u201360.","journal-title":"Am J Hematol"},{"issue":"7","key":"779_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.mayocp.2019.12.013","volume":"95","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Patnaik MM. Hereditary predisposition to hematopoietic neoplasms. Mayo Clin Proc. 2020;95(7):1482\u201398.","journal-title":"Mayo Clin Proc"},{"key":"779_CR8","doi-asserted-by":"crossref","unstructured":"Mangaonkar AA, Ferrer A, Pinto e Vairo F et al. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings. 2019;94(9):1753\u20131768.","DOI":"10.1016\/j.mayocp.2019.04.007"},{"issue":"12","key":"779_CR9","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/leu.2016.228","volume":"30","author":"E Negoro","year":"2016","unstructured":"Negoro E, Radivoyevitch T, Polprasert C, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"779_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ajh.25610","volume":"95","author":"I Abou Dalle","year":"2019","unstructured":"Abou Dalle I, Kantarjian H, Bannon SA, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2019;95(2):227\u20139.","journal-title":"Am J Hematol"},{"issue":"7","key":"779_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.25486","volume":"94","author":"AE Quesada","year":"2019","unstructured":"Quesada AE, Routbort MJ, DiNardo CD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019;94(7):757\u201366.","journal-title":"Am J Hematol"},{"issue":"17","key":"779_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134(17):1441\u20134.","journal-title":"Blood"},{"issue":"6","key":"779_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bjh.16668","volume":"192","author":"S Qu","year":"2020","unstructured":"Qu S, Li B, Qin T, et al. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. Br J Haematol. 2020;192(6):1006\u201310.","journal-title":"Br J Haematol"},{"issue":"7","key":"779_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2021015328","volume":"140","author":"N Duployez","year":"2022","unstructured":"Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756\u201368.","journal-title":"Blood"},{"issue":"11","key":"779_CR15","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41409-022-01776-6","volume":"57","author":"A Baranwal","year":"2022","unstructured":"Baranwal A, Nanaa A, Viswanatha D, et al. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. Bone Marrow Transplant. 2022;57(11):1716\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"779_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/ajh.27070","volume":"98","author":"A Bataller","year":"2023","unstructured":"Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023;98(11):1780\u201390.","journal-title":"Am J Hematol"},{"issue":"11","key":"779_CR17","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3324\/haematol.2023.282867","volume":"108","author":"T Badar","year":"2023","unstructured":"Badar T, Nanaa A, Foran JM, et al. Clinical and molecular correlates of somatic and germline\u2009<\u2009i>DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023;108(11):3033\u201343.","journal-title":"Haematologica"},{"issue":"4","key":"779_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/bjh.20018","volume":"206","author":"Y Kusne","year":"2025","unstructured":"Kusne Y, Badar T, Lasho T, et al. Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. Br J Haematol. 2025;206(4):1109\u201320.","journal-title":"Br J Haematol"},{"key":"779_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep17030026","author":"N Toumeh","year":"2025","unstructured":"Toumeh N, Jabban Y, Nanaa A, et al. Clinical outcome and molecular profile in patients with DDX41 mutation hot-spots. Hematol Rep. 2025. https:\/\/doi.org\/10.3390\/hematolrep17030026.","journal-title":"Hematol Rep"},{"key":"779_CR20","doi-asserted-by":"crossref","unstructured":"Korotev SC, Cheng JX, Haribabu Y et al. Overall cancer risk in people with deleterious germline\u2009<\u2009i>DDX41 variants. Haematologica. 2025.","DOI":"10.3324\/haematol.2024.286887"},{"issue":"1","key":"779_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1042\/BST20230725","volume":"52","author":"L Winstone","year":"2024","unstructured":"Winstone L, Jung Y, Wu Y. DDX41: exploring the roles of a versatile helicase. Biochem Soc Trans. 2024;52(1):395\u2013405.","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"779_CR22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/ajh.27091","volume":"98","author":"TM Chlon","year":"2023","unstructured":"Chlon TM, Patnaik MM. Germline DDX41 mutant predisposition syndromes: slow driver states to hematological malignancies. Am J Hematol. 2023;98(11):1673\u20136.","journal-title":"Am J Hematol"},{"issue":"5","key":"779_CR23","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s00277-025-06278-1","volume":"104","author":"L Miao","year":"2025","unstructured":"Miao L, Wang X, Yao M, Tao Y, Han Y. Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis. Ann Hematol. 2025;104(5):2581\u201391.","journal-title":"Ann Hematol"},{"issue":"11","key":"779_CR24","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/s41375-022-01708-9","volume":"36","author":"S Shinriki","year":"2022","unstructured":"Shinriki S, Hirayama M, Nagamachi A, et al. DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells. Leukemia. 2022;36(11):2605\u201320.","journal-title":"Leukemia"},{"issue":"4","key":"779_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.stemcr.2022.02.010","volume":"17","author":"J Ma","year":"2022","unstructured":"Ma J, Mahmud N, Bosland MC, Ross SR. DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice. Stem Cell Rep. 2022;17(4):879\u201393.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"779_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, Schulze I, Sekeres Mikkael A, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015;27(5):658\u201370.","journal-title":"Cancer Cell"},{"issue":"13","key":"779_CR27","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood.2022017715","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Bowman TV, Godley LA. DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023;141(13):1544\u201352.","journal-title":"Blood"},{"key":"779_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020344","author":"K Kim","year":"2023","unstructured":"Kim K, Ong F, Sasaki K. Current understanding of DDX41 mutations in myeloid neoplasms. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15020344.","journal-title":"Cancers"},{"issue":"2","key":"779_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","volume":"6","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha D, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022;6(2):528\u201332.","journal-title":"Blood Adv"},{"issue":"23","key":"779_CR30","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","volume":"7","author":"A Maierhofer","year":"2023","unstructured":"Maierhofer A, Mehta N, Chisholm RA, et al. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv. 2023;7(23):7346\u201357.","journal-title":"Blood Adv"},{"issue":"2","key":"779_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.seminhematol.2017.04.007","volume":"54","author":"JP Maciejewski","year":"2017","unstructured":"Maciejewski JP, Padgett RA, Brown AL, M\u00fcller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017;54(2):94\u20137.","journal-title":"Semin Hematol"},{"issue":"Supplement 1","key":"779_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2025-677","volume":"146","author":"R Venkataraman","year":"2025","unstructured":"Venkataraman R, Rahman J, Miyagawa T, et al. DDX41-R525H mutation promotes dysplastic hematopoiesis via aberrant splicing of key regulators of HSC biology. Blood. 2025;146(Supplement 1):677\u2013677.","journal-title":"Blood"},{"issue":"Supplement 1","key":"779_CR33","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/blood-2024-208467","volume":"144","author":"J Kida","year":"2024","unstructured":"Kida J, Fricker M, Stepanchick E, Chlon T. The most common somatic DDX41 mutation (p.R525H) causes loss of an essential function and is selected against in human iPSC and leukemia models. Blood. 2024;144(Supplement 1):4089\u20134089.","journal-title":"Blood"},{"issue":"5","key":"779_CR34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Saiki R, Nannya Y, et al. Germ lineDDX41mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141(5):534\u201349.","journal-title":"Blood"},{"key":"779_CR35","doi-asserted-by":"crossref","unstructured":"Ana CG, Cecilia PMO, Geraldine De L et al. First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype. Haematologica. 2020;105(10).","DOI":"10.3324\/haematol.2020.253070"},{"key":"779_CR36","doi-asserted-by":"crossref","unstructured":"Baliakas P, Tesi B, Cammenga J et al. How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms. HemaSphere. 2024;8(8).","DOI":"10.1002\/hem3.145"},{"issue":"14","key":"779_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood.2023020209","volume":"142","author":"S Cheloor Kovilakam","year":"2023","unstructured":"Kovilakam SC, Gu M, Dunn WG, et al. Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023;142(14):1185\u20131192. https:\/\/doi.org\/10.1182\/blood.2023020209","journal-title":"Blood"},{"key":"779_CR38","doi-asserted-by":"crossref","unstructured":"Villy M-C, Drouet Y, Larcher L et al. Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers. Eur J Hum Genet. 2025.","DOI":"10.1038\/s41431-025-01952-4"},{"issue":"8","key":"779_CR39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","volume":"127","author":"M Lewinsohn","year":"2016","unstructured":"Lewinsohn M, Brown AL, Weinel LM, et al. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016;127(8):1017\u201323.","journal-title":"Blood"},{"issue":"12","key":"779_CR40","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"21","key":"779_CR41","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373.","journal-title":"Blood"},{"key":"779_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00818-6","author":"A Al-Kali","year":"2023","unstructured":"Al-Kali A, Nanaa A, Viswanatha D, et al. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J. 2023. https:\/\/doi.org\/10.1038\/s41408-023-00818-6.","journal-title":"Blood Cancer J"},{"issue":"2","key":"779_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2024","unstructured":"Gangat N, Elbeih A, Ghosoun N, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol. 2024;100(2):260\u201371.","journal-title":"Am J Hematol"},{"key":"779_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025. https:\/\/doi.org\/10.1038\/s41408-025-01346-1.","journal-title":"Blood Cancer J"},{"issue":"10","key":"779_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ni.2091","volume":"12","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu Y-J. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12(10):959\u201365.","journal-title":"Nat Immunol"},{"issue":"4","key":"779_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","volume":"7","author":"C Saygin","year":"2023","unstructured":"Saygin C, Roloff G, Hahn CN, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023;7(4):549\u201354.","journal-title":"Blood Adv"},{"issue":"24","key":"779_CR47","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1182\/bloodadvances.2025017084","volume":"9","author":"M Loschi","year":"2025","unstructured":"Loschi M, Villy M-C, Galimard J-E, et al. Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies. Blood Adv. 2025;9(24):6314\u201325.","journal-title":"Blood Adv"},{"issue":"25","key":"779_CR48","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"779_CR49","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","volume":"7","author":"AS Al-Homsi","year":"2023","unstructured":"Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023;7(14):3604\u201311.","journal-title":"Blood Adv"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00779-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:15:51Z","timestamp":1776939351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00779-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00779-0","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}